KRAS and non-small cell lung carcinoma: Meanwhile, KRAS/TP53-comutated LUAD tumors manifested increased expressions of PD-1 and PD-L1, a high accumulation of CD8+ tumor-infiltrating lymphocytes and high mutational loads, and NSCLC patients with co-occurring KRAS/TP53 mutations showed a favorable clinical benefit with anti-PD-1 therapy [65].